Localized scleroderma.
OBJECTIVE
Localized scleroderma, also known as morphoea, has a variety of clinical manifestations that can include systemic involvement. Early recognition, diagnosis and treatment may improve the long-term outcome.


RESULTS
A large multicentre study coordinated by the Pediatric Rheumatology European Society has yielded important information on the epidemiology and clinical manifestations of juvenile localized scleroderma, especially as it pertains to systemic manifestations. Previous results using methotrexate and corticosteroids have been confirmed. Studies on phototherapy have also demonstrated efficacy. A new immunomodulator, imiquimod, has shown promise in an initial case series.


CONCLUSIONS
Studies over the past year highlight the wide range of extracutaneous manifestations and different forms of localized scleroderma and suggest that treatment may be beneficial.
Laxer
Ronald M
RM
Department of Paediatrics and Medicine, University of Toronto, Vice President, Education and Quality, The Hospital for Sick Children, Toronto, Canada. ronald.laxer@sickkids.ca
Zulian
Francesco
F
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D012594:Scleroderma, Localized / Q000276:immunology / Q000473:pathology / Q000628:therapy